THERAPY DOSSIER · th-58c68b57dc0d

Sodium hydrosulfide (NaHS, hydrogen sulfide donor), with the cystathionine-gamma-lyase inhibitor propargylglycine as the opposing intervention

Drug · H2S donor; not a discrete ChEMBL drug (nearest entry SODIUM SULFIDE, CHEMBL2107611)

Evidence & regulatory context

Mechanism: H2S donor; not a discrete ChEMBL drug (nearest entry SODIUM SULFIDE, CHEMBL2107611)
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: NaHS
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23122581 ↗2012Reported benefit

Inhibition of hydrogen sulfide generation contributes to lung injury after experimental orthotopic lung transplantation.

RatIschaemia-reperfusionOther / unspecifiedSprague-DawleymaleIntraperitonealNaHS 14 µmol/kg; propargylglycine 37.5 mg/kg15 minutes before the start of lung transplantation

Model: Single left orthotopic lung transplantation after 3 h of cold ischaemia time

NaHS improved pulmonary function and decreased lipid peroxidation, myeloperoxidase activity and interleukin 1β while increasing interleukin 10 in lung grafts, whereas propargylglycine worsened pulmonary function and lung injury.

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…